Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Net Income: 2017-2025

Historic Net Income for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to -$79.1 million.

  • Autolus Therapeutics' Net Income rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Net Income is -$79.1 million, which was down 65.11% from -$47.9 million recorded in Q2 2025.
  • Autolus Therapeutics' Net Income's 5-year high stood at -$6.8 million during Q4 2021, with a 5-year trough of -$44.8 billion in Q3 2021.
  • Its 3-year average for Net Income is -$56.9 million, with a median of -$52.7 million in 2024.
  • Per our database at Business Quant, Autolus Therapeutics' Net Income tumbled by 84,283.07% in 2021 and then soared by 99.90% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Net Income (Quarterly) stood at -$6.8 million in 2021, then tumbled by 298.16% to -$27.0 million in 2022, then crashed by 186.04% to -$77.2 million in 2023, then surged by 64.23% to -$27.6 million in 2024, then increased by 3.63% to -$79.1 million in 2025.
  • Its last three reported values are -$79.1 million in Q3 2025, -$47.9 million for Q2 2025, and -$70.2 million during Q1 2025.